Consensus Xencor, Inc.

Stocks

XNCR

US98401F1057

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-09-24 EDT			5-day change	1st Jan Change
23.88 ^USD	-1.57%		+0.72%	+55.98%

09-01	Raymond James Adjusts Xencor Price Target to $46 From $40, Maintains Strong Buy Rating	MT
08-06	Wedbush Adjusts Price Target on Xencor to $30 From $26, Maintains Outperform Rating	MT

Evolution of the Average Target: Xencor, Inc.

Evolution of the Target Price: Xencor, Inc.

Changes in Analyst Recommendations: Xencor, Inc.

3bc1ec35.Z0UEPhNevIT39aoO2r1DbfwOMyQ7ztAKcPSTAZpa-b8.IzRJEyYw17a1kfBf4t4HActvfRZLuLNlMpL5cd8yiM0DNXdmKgTswMGm-w~fa4a20f04465a85da66336eb7cb90ea1

Analysts' recommendations: Xencor, Inc.

09-21	BofA Adjusts Price Target on Xencor to $26 From $20, Keeps Neutral Rating	MT
09-01	Raymond James Adjusts Xencor Price Target to $46 From $40, Maintains Strong Buy Rating	MT
08-06	Wedbush Adjusts Price Target on Xencor to $30 From $26, Maintains Outperform Rating	MT
08-06	RBC Capital Adjusts PT on Xencor to $20 From $19, Maintains Outperform Speculative Risk Rating	MT
03-24	Xencor Shares Fall After JPMorgan Downgrade	MT
03-24	JPMorgan Downgrades Xencor to Neutral From Overweight, Adjusts PT to $13 From $18	MT
11-06	RBC Raises Price Target on Xencor to $19 From $18, Keeps Outperform, Speculative Risk	MT
25-10-29	Xencor Shares Rise After Barclays Upgrade	MT
25-10-29	Barclays Upgrades Xencor to Overweight From Underweight, Adjusts Price Target to $23 From $6	MT
25-10-27	RBC Raises Price Target on Xencor to $18 From $15, Keeps Outperform, Speculative Risk	MT
25-10-24	Xencor, Inc. Presents Initial Data for XmAb819, a First-In-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma	CI
25-10-14	Xencor Shares Fall After Early Commentary on Kidney Cancer Drug Trial Abstract	MT
25-09-03	Xencor Shares Fall After BofA Securities Downgrade	MT
25-09-03	BofA Securities Downgrades Xencor to Neutral From Buy	MT
25-08-21	RBC Cuts Price Target on Xencor to $15 From $32, Keeps Outperform, Speculative Risk	MT
25-08-07	Wedbush Cuts Price Target on Xencor to $26 From $31, Keeps Outperform Rating	MT
25-04-21	William Blair Initiates Xencor at Outperform	MT
25-02-28	RBC Capital Adjusts Xencor Price Target to $32 From $34, Maintains Outperform - Speculative Risk Rating	MT
25-02-28	Wedbush Cuts Price Target on Xencor to $31 From $38, Keeps Outperform Rating	MT
24-12-12	Wells Fargo Initiates Xencor at Overweight With $37 Price Target	MT
24-12-02	Piper Sandler Upgrades Xencor to Overweight, Price Target is $30	MT
24-09-26	RBC Raises Price Target on Xencor to $34 From $31, Keeps Outperform, Speculative Risk	MT
24-06-14	Raymond James Adjusts Price Target on Xencor to $40 From $58, Maintains Strong Buy Rating	MT
24-06-14	BMO Capital Adjusts Xencor's Price Target to $32 From $34, Keeps Outperform Rating	MT
24-06-14	RBC Trims Price Target on Xencor to $31 From $32, Maintains Outperform, Speculative Risk Rating	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	XENCOR, INC.					+28.81%
	WUXI APPTEC CO., LTD.					+11.38%
	ARGENX SE					+23.5%
	INSMED INCORPORATED					+68.62%
	BIONTECH SE					+19.14%
	GENMAB A/S					+0.49%
	PHARMAESSENTIA CORPORATION					+18.92%
	EXELIXIS, INC.					-5.36%
	SUMMIT THERAPEUTICS INC.					+76.86%
	MADRIGAL PHARMACEUTICALS, INC.					+32.71%
	Average					+27.51%
	Weighted average by Cap.					+23.58%